Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
Abnormal liver enzymes (LE) are common in patients infected with the human immunodeficiency virus (HIV) even in the absence of viral hepatitis or alcohol abuse. With availability of antiretroviral combination therapy, life expectancy has improved dramatically and as a consequence the spectrum of liver disease is changing. Increased reports on the development of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in HIV coinfected patients raise questions around prevalence, clinical manifestations, and clinical outcome of these liver diseases in HIV coinfection. Moreover, the potential impact of combination antiretroviral therapy as well as direct HIV effects on the emergence of non-alcoholic fatty liver disease needs to be explored. This review summarizes the recent literature on NAFLD and NASH in HIV.
KeywordsLiver fibrosis Nash NAFLD HIV
This work was supported by the DZIF TTU HIV Project 05.803 and the German Center for Infection Research (DZIF).
Compliance with Ethical Standards
Conflict of Interest
Jürgen Kurt Rockstroh reports honoraria for speaking at educational events or consulting from Abbott, Abbvie, Bionor, BMS, Cipla, Gilead, Hexal, Janssen, Merck, and ViiV.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 3.•• Morse CG, McLaughlin M, Matthews L, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis. 2015;60(10):1569–78.2. One of the few liver biopsy studies in HIV-infected adults with aminotransferase levels elevated above the upper limit of normal for ≥6 months while receiving ART, and without chronic viral hepatitis or other known causes of chronic liver disease. Interestingly, HIV-infected adults with chronic aminotransferase elevations while receiving ART had a high rate of liver disease (55% NASH) PubMedPubMedCentralGoogle Scholar
- 6.Rivero-Juárez A, Camacho A, Merchante N, et al. Grupo para el estudio de las hepatitis vı’ricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS One. 2013;8(7):e68953.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.•• European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. Clinically extremely useful guidelines around all major aspects of fatty liver disease including disease definitions and treatment recommendations . Google Scholar
- 14.Macías J, Real LM, Rivero-Juárez A, et al. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. HIV Med. 2016.Google Scholar
- 17.•• Jiménez-Sousa MA, Berenguer J, García-Álvarez M, et al. Impact of patatin-like phospholipase domain-containing 3 gene polymorphism (rs738409) on severity of liver disease in HIV/hepatitis C virus-coinfected patients. AIDS. 2016;30(3):465–70. This cross-sectional study analyses the association between patatin-like phospholipase domain-containing 3 gene (PNPLA3) rs738409 polymorphism and severity of liver disease in HIV/hepatitis C virus-coinfected patient. Indeed, PNPLA3 rs738409 polymorphism was associated with the severity of liver fibrosis in patients coinfected with HIV and hepatitis C virus, suggesting that this polymorphism might also play a significant role in the progression of hepatic fibrosis in this group of patients CrossRefPubMedGoogle Scholar
- 20.Dillon SM, Frank DN, Wilson CC. The gut microbiome and HIV-1 pathogenesis: a two way street. AIDS. 2016;14.Google Scholar
- 22.Rial SA, Karelis AD, Bergeron KF, et al. Gut microbiota and metabolic health: the potential beneficial effects of a medium chain triglyceride diet in obese individuals. Nutrients. 2016;8(5).Google Scholar
- 23.Houghton D, Thoma C, Hallsworth K, et al. Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2016.Google Scholar
- 27.Shlay JC, Visnegarwala F, Bartsch G, et al. Terry Beirn community programs for clinical research on AIDS (CPCRA). Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147–55.CrossRefPubMedGoogle Scholar